Diazepan Compounds as Orexin Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with orexin receptor dysfunction lack effective antagonists that can specifically target and inhibit orexin receptor activity, leading to inadequate management of conditions such as sleep disorders, depression, anxiety, and addiction.
Innovation Solution
Development of diazepan compounds that act as antagonists of orexin receptors, specifically designed to inhibit orexin receptor activity, which are administered in pharmaceutical compositions to treat various neurological and psychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurological and psychiatric disorders, then existing therapeutic options are available, but effective antagonists that can specifically target and inhibit orexin receptor activity are lacking
Solution Approach 1:
The invention segments the broad category of neurological and psychiatric disorders into specific conditions mediated by orexin receptors, developing targeted antagonists for OX1R and OX2R. This allows specific therapeutic intervention for disorders like narcolepsy, insomnia, depression, and anxiety by blocking orexin receptor activity rather than using broad-spectrum treatments.
Solution Approach 2:
The diazepan compounds act as intermediary substances that block the interaction between orexin neuropeptides and their receptors. These compounds serve as mediators that prevent orexin from binding to OX1R and OX2R, thereby inhibiting the downstream signaling pathways that mediate various neurological and psychiatric disorders.
2Adaptability or versatility
If diazepan compounds are developed as orexin receptor antagonists, then specific inhibition of orexin receptor activity is achieved, but new compound development and validation are required
Solution Approach 1:
The invention modifies chemical parameters of diazepan core structures by varying substituents at different positions (R1, R2, R3 groups) to optimize receptor binding affinity and selectivity. By systematically changing molecular parameters such as substituent types, positions, and configurations, the invention achieves high specificity for orexin receptors while maintaining manageable synthesis complexity.
Solution Approach 2:
The invention introduces specific functional groups and substituents at particular positions on the diazepan ring structure to enhance local interactions with orexin receptors. The R1, R2, and R3 substituents are strategically placed to create localized binding features that recognize specific amino acid residues in the receptor binding pocket, thereby achieving high specificity.
3Reliability
If diazepan compounds are administered for therapeutic benefit, then treatment of neurological and psychiatric disorders is achieved, but oral bioavailability and metabolic stability must be optimized
Solution Approach 1:
The invention optimizes pharmacokinetic parameters by modifying the diazepan compound structure to improve oral bioavailability and metabolic stability. This includes adjusting lipophilicity, molecular weight, and metabolic stability through strategic substitution patterns that enhance absorption while reducing first-pass metabolism and hepatic clearance.
Solution Approach 2:
The invention develops compounds with appropriate metabolic stability profiles that allow for effective therapeutic concentrations to be maintained without requiring excessive dosing. The compounds are designed to have sufficient half-life for clinical efficacy while being metabolized to inactive products, balancing persistence with safety.
Data Source
AI summary
The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.